What we do
Bukwang Pharmaceutical Company Limited has a firm focus on Research and Development (R&D) and a vision to become a world class pharmaceutical company through continuous innovation. We were nominated as the “Korea Innovative Pharmaceutical Company” by the Korean government, which acknowledges our commitment to innovation in drug development.
Bukwang is experienced in new drug development, owing to our successful development of Levovir (clevudine), as the 4th new drug for hepatitis B in the world and 1st in Asia. Based on this experience, we are forming a pipeline that combines drug repositioning and open innovation, while also expanding our global network.
Bukwang has extensive experiences in new drug development through multinational clinical trials with global CROs and CMOs. We are composed of specialists in Clinical, Regulatory, and Product Development areas. Our expertise spans the whole process of product development from the early stage to the post-marketing stage.
Bukwang is looking for innovative products with which to expand our pipeline. With a committed team of experts, we are reveiwing more than 300 potential candidates under development globally every year. We licensed MLR-1023 from Melior Pharmaceuticals I in the US and JM-010 from Contera Pharma in Denmark. The former is a novel agent against Type 2 Diabetes, while the latter is a new drug candidate for LID (Levodopa-induced dyskinesia) in Parkinson’s patients.
Bukwang has maintained positive cooperative partnership with overseas partners based in various countries, from Japan to USA to the European continent. We are more than happy to discuss potential therapeutic candidates and products ready for registration and commercialization.
How we partner
Bukwang has experience in partnering in many forms, including license agreement, co-development, M&A and direct investment. If you would like to discuss potential partnership arrangement with Bukwang,
please send us your suggestion to the following link : email@example.com